Leerink Sees Attractive Risk-Reward in Stryker (SYK) Despite First-Quarter Revenue Miss

Stryker Corporation (NYSE:SYK) ranks among the best set-it-and-forget-it stocks to buy right now. On June 5, Leerink reduced its price target for Stryker Corporation (NYSE:SYK) to $407 from $410 while keeping an Outperform rating on the company’s stock. The firm changed its SYK model in response to new 10-Q filings following the company’s first-quarter 2026 results.

The company fell short of analysts’ forecasts, reporting earnings per share of $2.60 vs an estimate of $2.98, with revenue of $6 billion coming below an expected $6.34 billion. Despite these challenges, Stryker Corporation (NYSE:SYK) has reiterated its 2026 projection.

The fiscal 2026 earnings per share projection fell by $0.01, reflecting management’s statement that a significant portion of the revenue deficit in the first quarter due to a cyberattack is expected to be recovered in the second half of the year. The firm’s EPS expectations for fiscal 2027 and fiscal 2028 were reduced by about 1% to reflect the impact of the most recent disclosures.

Leerink, however, stated that it still sees a solid risk/reward skew for Stryker Corporation (NYSE:SYK) and thinks the company is still among the better-positioned names in large-cap medical technology.

Founded in 1981, Stryker Corporation (NYSE:SYK) is a leading provider of medical technology products and services. Its business operations are divided into three primary divisions: Orthopedics, MedSurg, and Neurotechnology and Spine.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.